Drug combo for advanced colorectal cancer that hasn't spread to the liver
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (anlotinib and sintilimab) as a first treatment for people with advanced colorectal cancer that has spread to places other than the liver, who do not want chemotherapy. The goal is to see if this targeted therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that has spread to areas other than the liver.
- You have not had chemotherapy for advanced disease (or if you did, it was at least a year ago).
- You are willing to not receive chemotherapy for this cancer.
- You have at least one tumor that can be measured on scans.
- You are 18 or older and in generally good health (able to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two medicines, pin and sintilimab, for people with advanced colorectal cancer that has spread to the liver and has already been treated with at least two standard therapies. The study aims to see if injecting the medicine directly into the liver tumor, combined with immunotherapy through a vein, can shrink tumors and help patients live longer.
This trial tests a combination of two extra drugs (pirfenidone and sintilimab) added to standard chemotherapy before surgery. The goal is to see if this combination can help shrink or control colorectal cancer that has spread to the lining of the abdomen.
This study tests a new combination of three drugs for advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow down the cancer's growth.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
This trial tests a combination therapy that includes an immunotherapy drug (called anti-PD-1) for people with rectal cancer that has spread to the liver or lungs. The goal is to see if this treatment can help shrink or control the cancer, and it may be an option if you haven't had treatment yet.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.